Study Finds ABP 215 and Bevacizumab Demonstrate PK Similarity in Japanese MenNovember 18th 2018
The researchers say that their data were consistent with the pharmacokinetic equivalence previously demonstrated in a single-dose PK study that included 202 healthy adult men in the United States and European Union, and thus add to the evidence of ABP-215 as a high-quality biosimilar to bevacizumab for use in Japan.
Research Underscores Rituximab's Utility in Treating MSNovember 15th 2018
Rituximab is frequently used off-label as a treatment for relapsing-remitting multiple sclerosis (MS) because it induces the depletion of circulating B-cell and T-cell lymphocytes and targets CD20 protein in B cells that are responsible for the production of antibodies.
Does Biosimilar Infliximab Have a Role After Secondary Loss of Response to Its Reference?November 15th 2018
Results of a small Greek observational study suggest that biosimilar infliximab may be an effective alternative for the treatment of patients with inflammatory bowel disease (IBD) who have active disease and experienced a loss of response to innovator infliximab (Remicade).
US Drug Prescription Rates Influenced by Race, State Healthcare Laws, and WealthNovember 14th 2018
The best predictors of which US counties’ patients are most likely to be prescribed higher-priced drugs are income, healthcare costs, and access to exercise opportunities, according to a new study published online in Nature Communications.
First-Line Bevacizumab More Effective in MBC Not Previously Treated with TaxanesNovember 14th 2018
Among long-term responders, first-line bevacizumab-based therapy is more effective in patients with HER2-negative metastatic breast cancer (MBC) who were not previously treated with taxanes, a recent Spanish study suggests.
Patients With CLL Who Have Anaphylaxis With Obinutuzumab May Be Able to Receive RituximabSeptember 16th 2018
Rituximab-based immunochemotherapy can be safely applied in patients after obinutuzumab-associated anaphylaxis, but the existing risk of cross­reactivity should be considered, and careful monitoring of such patients during rituximab infusion is required.
Review Urges Better Guidelines for Optimal Management of Patients With Crohn DiseaseSeptember 14th 2018
Up to 60% of Crohn disease patients taking an anti—tumor necrosis factor (TNF) monoclonal antibody medication eventually stop responding to treatment, but the optimal management of these patients has not been clearly defined.
Study Suggests Predictive Biomarker for Therapeutic Outcomes in Ankylosing SpondylitisSeptember 14th 2018
A new study suggests that CD8+ natural killer cells are a biomarker that can predict therapeutic outcome for patients with ankylosing spondylitis who are administered anti–tumor necrosis factor agents because they are nonresponsive to conventional treatment.
Switching From Reference Adalimumab to Biosimilar ABP 501 Does Not Cause ImmunogenicityJuly 13th 2018
Transitioning from reference adalimumab (Humira) to Amgen’s FDA- and EU-approved adalimumab biosimilar ABP 501 (Amgevita) was not associated with increased immunogenicity over an observation period of 72 weeks in patients with rheumatoid arthritis, according to the results of a study presented at the European Congress of Rheumatology.
Low-Dose Strategy for Etanercept in Psoriatic Arthritis Can Maintain RemissionJuly 11th 2018
Italian researchers report that 72% of their trial participants being treated for psoriatic arthritis achieved sustained remission with ETN 25 mg biweekly, which was maintained a year after treatment initiation.
Study Finds Significant Unmet Needs Remain With RA TreatmentJuly 10th 2018
Despite progress in the successful treatment of patients with rheumatoid arthritis (RA) who are using conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) and biological DMARDs (bDMARDs), a Greek study has found that a considerable number of patients are still not achieving low disease activity (LDA) despite having been treated following established recommendations for RA therapy.
Observational Study Finds High Patient Satisfaction With Prefilled Biosimilar SB4 PenJuly 6th 2018
A survey of German patients who used a prefilled pen for subcutaneous delivery of biosimilar etanercept SB4 has reported a very high level of patient satisfaction with the product following an interim analysis.
Nonmedical Switching to Biosimilar in Stable Rheumatic Diseases Associated With Considerable Short-Term CostsJuly 5th 2018
In the short term, nonmedical switching (NMS) of stable patients with a rheumatic condition from originator biologics to biosimilars could have “considerable” short-term costs for a rheumatology medical center, according to a study presented at the annual European Congress of Rheumatology.
Norwegian Study Finds Nonmedical Switch to Biosimilar Etanercept SB4 Well Tolerated in RAJuly 3rd 2018
A preliminary study among patients with rheumatoid arthritis (RA) in Norway who were switched from originator etanercept to its biosimilar (SB4) for nonmedical reasons found that patients had good tolerance for the switch to the biosimilar, with no impairment in disease measures.
Canada Allows Aligned Regulatory Drug Reviews Between Health Canada and HTA OrgsJune 29th 2018
Health Canada, Canada’s governmental health agency, announced that there is now an option for all biological and pharmaceutical new drug submissions to request aligned regulatory reviews between Health Canada and health technology assessment (HTA) organizations.
Study Shows Association Between Health Literacy and Patient Satisfaction With Switching to BiosimilarJune 28th 2018
Research presented at the European League Against Rheumatism’s Annual European Congress of Rheumatology concluded that patients’ attitudes and level of satisfaction with switching to a biosimilar for etanercept or infliximab was associated with their level of health literacy, defined as being given sufficient and necessary information concerning their health.
ILAR Treatment Recommendations for Psoriatic Arthritis in Resource-Poor Countries AvailableJune 28th 2018
New International League of Associations for Rheumatology (ILAR) recommendations are now available for the treatment of patients with psoriatic arthritis living in resource-poor regions, including Central and South America and Africa.
Dutch Study at EULAR Evaluates Impact of Switch From Originator to Biosimilar EtanerceptJune 26th 2018
The study, conducted in 80 patients with rheumatic diseases who elected to switch from treatment with originator etanercept to biosimilar etanercept, found that 80% were willing to switch, and switching did not affect treatment effectiveness during 1 year of follow up.
Report Details Novel Methods to Improve Clinical Use of CAR T-Cell ImmunotherapiesJune 25th 2018
Researchers have reported the development of CubiCAR architecture, which has the potential to improve the safety of chimeric antigen receptor (CAR) T-cell immunotherapies for a broad range of patients with cancer.
High Rate of Inadequate Response to Biologics In Patients Initiating Treatment for RAMay 23rd 2018
More than two-thirds of patients with rheumatoid arthritis (RA) previously naïve to biologic disease-modifying anti-rheumatic drugs had an inadequate response to their first biologic during 1 year of follow up, according to a recent Taiwanese study.
No Difference in Quality of Glycemic Control With Biosimilar Versus Originator InsulinMay 22nd 2018
An Asian study comparing the quality of glycemic control among patients using biosimilar insulin with those using originator insulin found no independent association of biosimilar insulin with differences in indicators of glycemic control—glycated hemoglobin, insulin dosage, or hypoglycemia.
HLA Alleles May Play a Role in Formation of Anti-Drug Antibodies to AdalimumabMay 21st 2018
Specific human leukocyte antigen (HLA) alleles are associated with the formation of anti-drug antibodies to adalimumab in patients with rheumatoid arthritis and hidradenitis suppurativa, potentially causing reduced therapeutic response.
Cyclophosphamide-Bevacizumab as Second-Line Chemo in Advanced Recurrent Cervical CancerMay 7th 2018
Some cervical cancer patients with advanced or recurrent disease suffer from anaphylaxis after taxane- or platinum-based therapy, and there is no standard treatment for progressive disease that develops during or shortly after platinum-based chemotherapy. Doctors and patients have therefore sought the development of a non-taxane, non-platinum regimen for recurrent cervical cancer.